Read Our Recent News
NanoMab Announces First Patient Dosed in Phase II Clinical Trial of Novel Radiolabelled Single Domain Antibody (NM-01) in Patients with Non-Small Cell Lung Cancer
London, May 17, 2022 - NanoMab Technology Limited, a privately held biopharmaceutical company focussing on the development of next generation radiopharmaceuticals for cancer precision therapies, today announced the dosing of the first patient in a phase II clinical trial in partnership with Lantheus and King’s College London. The phase II trial is a non-randomised, non-blinded, single centre study evaluating PD-L1 expression in Non-small Cell Lung Cancer (NSCLC) patients using 99mTc Labelled Anti-PD-L1 single domain antibody (NM-01). NM-01 is a camelid single-domain antibody (sdAb) [...]
NanoMab Announces Strategic Leadership Changes
London, April 29th, 2022 - NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies is thrilled to announce the well-deserved promotion of Dr. Gitasha Chand to Managing Director and Dr. Levente Meszaros to Director of Technical Operations of NanoMab Technology (UK) Ltd. Dr. Chand, who most recently held the position of Clinical Research Director, has been committed to NanoMab since it was founded in 2016 and her extensive experience in the development of radiopharmaceuticals and early phase clinical trials [...]
NanoMab Technology Limited signs licensing agreements with Radiopharm Theranostics and Full Life Technologies (HK) Ltd.
London, April 12th, 2022 - NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies is delighted to announce that over the course of the last two quarters it has taken the next steps forward in its commitment to developing next generation pharmaceuticals by forming exclusive licensing agreements with Radiopharm Theranostics (ASX: RAD) and Full Life Technologies (HK) Ltd. The agreements grant RAD full rights to develop three of NanoMab’s single-domain antibody assets: NM-02, NM-03, and NM-04; respectively targeting HER-2 [...]
Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.
Thanks to the great support from our collaboration partner LMI , NanoMab has reached another milestone with this Tc-99m NM01 DMF filing with FDA after its MHRA Approval into Phase 2 trial in UK ! Lantheus' Press Release
Paul Edwards’ Editorial on ‘Drug Discovery Today’
Why next generation radiopharma-ceuticals will play a key role in the quest for precision medicine. https://www.sciencedirect.com/science/article/pii/S1359644620304190
NanoMab receives MHRA approval to commence a Phase 2 Clinical Study to investigate PD-L1 expression using its NM-01 product as a tool for non-invasive in vivo imaging.
London, November 4th, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had received CTA Acceptance from the Medicines Healthcare products Regulatory Agency (MHRA) to carry out a Phase II clinical Study for its NM-01 product. The study (“PELICAN”) will investigate the assessment of programmed death ligand 1 (PD-L1) expression using 99mTc-NM-01 as a SPECT/CT radiotracer and its correlation to PD-L1 expression results based on routine immunohistochemical (IHC) testing in biopsy diagnostic specimens. The [...]